Clinical Trial Update: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment [Phase 3]

View source ↗

Summary

A Phase III clinical trial is evaluating capivasertib plus standard endocrine therapy in HR-positive, HER2-negative advanced breast cancer that progressed on pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer, HR-positive Breast Cancer | Phase 3 | Status: RECRUITING